Please use this identifier to cite or link to this item: https://doi.org/10.1002/jms.3095
DC FieldValue
dc.titleQuantification of ginsenosides Rh4 and Rk3 in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pre-clinical pharmacokinetic study
dc.contributor.authorPatel, D.N.
dc.contributor.authorLin, H.-S.
dc.contributor.authorKoh, H.-L.
dc.date.accessioned2014-10-29T01:57:38Z
dc.date.available2014-10-29T01:57:38Z
dc.date.issued2012-11
dc.identifier.citationPatel, D.N., Lin, H.-S., Koh, H.-L. (2012-11). Quantification of ginsenosides Rh4 and Rk3 in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pre-clinical pharmacokinetic study. Journal of Mass Spectrometry 47 (11) : 1510-1517. ScholarBank@NUS Repository. https://doi.org/10.1002/jms.3095
dc.identifier.issn10765174
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/106274
dc.description.abstractGinsenoside Rh4 (Rh4) and ginsenoside Rk3 (Rk3) are two active substances isolated from the processed Panax species. To further explore their potential medicinal application, a reliable liquid chromatography-tandem mass spectrometry method (LC/MS/MS) was developed and validated for the quantification of Rh4 and Rk3 in rat plasma. Multiple ion monitoring and multiple reaction monitoring experiments were performed in negative ionization mode. This LC/MS/MS method had good selectivity, sensitivity (lower limit of quantification = 10 ng/mL), precision (intra- and inter-day relative standard deviation ≤ 10.1) and accuracy (analytical recovery within 100 ± 10%). The pharmacokinetic profiles of Rh4 and Rk3 were subsequently assessed in Sprague-Dawley rats. Similar to many other ginsenosides, the oral bioavailability of Rh4 and Rk3 was unfavorable, and Rh4 and Rk3 did not have any measurable plasma exposure after oral administration (20 mg/kg). Fortunately, upon intravenous administration (5 mg/kg), both Rh4 and Rk3 possessed abundant plasma exposure, moderate clearance (Cl = 50.2 ± 7.7 and 23.8 ± 1.4 mL·min -1·kg-1, respectively) and terminal elimination half-life (t1/2 λZ = 157.2 ± 65.2 and 99.5 ± 37.8 min, respectively). As Rh4 and Rk3 displayed favorable intravenous pharmacokinetic profiles, further exploration on their medicinal application is warranted. Copyright © 2012 John Wiley & Sons, Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1002/jms.3095
dc.sourceScopus
dc.subjectginsenoside Rh4
dc.subjectginsenoside Rk3
dc.subjectLC/ESI/MS/MS
dc.subjectpharmacokinetics
dc.subjectsteam processed ginseng
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.1002/jms.3095
dc.description.sourcetitleJournal of Mass Spectrometry
dc.description.volume47
dc.description.issue11
dc.description.page1510-1517
dc.description.codenJMSPF
dc.identifier.isiut000311093400018
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Dec 3, 2019

WEB OF SCIENCETM
Citations

7
checked on Dec 3, 2019

Page view(s)

56
checked on Nov 30, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.